Conor Medsystems current efforts are focused on bringing to market a drug-eluting vascular stent that represents a next generation sophistication in design and function over existing coated stents. The Conor MedStent’s proprietary technology presents expanded therapeutic opportunities for coronary and peripheral vascular disease. Nonvascular applications including Oncology are being reviewed as well. Conor’s technology is based on targeted and controlled drug eluting platforms. By delivering drugs during a specified release period directly to a target site, the stent platform provides multiple treatment options and flexibility.